PI_NAMEs: LI, MING  (contact)

PROJECT_TERMS: Biometry;California;Code;Collaborations;Collection;Common Data Element;Communication;Computer software;computerized data processing;Consultations;cost effective;Cross-Sectional Studies;Custom;Data;Data Analyses;data cleaning;Data Collection;data integration;data management;data platform;Data Science;Data Set;data sharing;Data Storage and Retrieval;data streams;Databases;design;Development;Ensure;experience;experimental study;Future;Generations;Goals;Human Resources;Informatics;Interdisciplinary Study;Investigation;longitudinal analysis;Longitudinal Studies;Manuscripts;Marketing;member;Methodology;Michigan;Modernization;Monitor;multidisciplinary;multilevel analysis;Output;Participant;Policies;Principal Investigator;Process;process optimization;programs;Protocols documentation;Publications;Publishing;Regulation;Reporting;Research;Research Design;Research Personnel;research study;Science;Services;Specialist;Statistical Methods;Surveys;Text;Tobacco;tobacco products;tool;Translations;Universities;usability;user-friendly;Work

PROJECT_TITLE: DPAC

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-ICN-R]


ADMINISTERING_IC: CA

ARRA_FUNDED: N

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Cancer Genomics;Gene Therapy;Genetics;Human Genome;Immunotherapy;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: MEMPHIS

ORG_COUNTRY: UNITED STATES

ORG_FIPS: US

ORG_NAME: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

ORG_STATE: TN

PHR: NARRATIVE The overall goal of this proposal is to evaluate the impact of DNA methylation inhibition of tumor cells, CAR T cells, and combined towards more effective treatments against diffuse midline glioma. Our secondary goal is to understand the treatment naïve microenvironment in DMG and how this environment changes in response to DNA methylation inhibition and CAR T cell administration. Our studies may pave the way for more effective treatments against DMG, a universally fatal disease with limited treatment options.

PI_NAMEs: KRENCIUTE, GIEDRE ;MACK, STEPHEN C (contact);PHOENIX, TIMOTHY N

PROGRAM_OFFICER_NAME: LIU, YIN

PROJECT_TERMS: Animal Model;Biological Models;Brain Neoplasms;cancer cell;CAR T cell therapy;Cell Physiology;Cell Therapy;Cells;Chemicals;Childhood Brain Neoplasm;chimeric antigen receptor;chimeric antigen receptor T cells;Clinical Research;combinatorial;Data;demethylation;Development;diffuse midline glioma;Disease;DNA;DNA Methylation;DNA Methylation Inhibition;DNA Modification Process;effective therapy;effector T cell;Elements;Environment;Epigenetic Process;epigenome;Evaluation;exhaustion;Frequencies;Future;Genetic;genetic selection;Genetic Transcription;Goals;H3 K27M mutation;human disease;Immune;immune cell infiltrate;Immune checkpoint inhibitor;Immune response;Immune system;Immunocompetent;immunodeficiency;Immunologic Stimulation;Immunotherapy;improved;In Vitro;in vivo;inhibitor;innate immune pathways;innovation;insight;Malignant Childhood Neoplasm;Malignant Neoplasms;methylome;Modeling;Molecular;mouse model;multidisciplinary;neoplastic cell;novel;Patients;pharmacologic;Phenotype;Population;Pre-Clinical Model;prevent;Process;programs;recruit;Recurrent tumor;Resistance;response;Solid Neoplasm;T cell therapy;T-Cell Activation;T-Cell Receptor Therapy;T-Lymphocyte;Technology;Testing;Therapeutic;Transferase;Translating;translational medicine;Translational Research;tumor;tumor DNA;tumor microenvironment;Work;Xenograft procedure

PROJECT_TITLE: Targeting tumor and T cell DNA methylomes to improve CAR T cell therapies for diffuse midline glioma


ADMINISTERING_IC: DK

FUNDING_MECHANISM: RESEARCH CENTERS

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

ORG_CITY: CINCINNATI

ORG_NAME: CINCINNATI CHILDRENS HOSP MED CTR

ORG_STATE: OH

PHR: PROJECT NARRATIVE Our Cystic Fibrosis (CF) Center at Cincinnati Children’s Hospital Medical Center (CCHMC) already has an excellent electronic medical record system (EPIC) and a site-specific IRB approved genotype database available for clinical and research use. We intend to leverage these capabilities to develop Personalized Cystic Fibrosis Therapy and Research Center (PCFC) for individual patients to determine his/her susceptibility to a particular form of CF mutation, and take steps to mitigate the early onset of the disease.

PI_NAMEs: AMIN, RAOUF S.;HELMRATH, MICHAEL A.;NAREN, ANJAPARAVANDA P (contact)

PROGRAM_OFFICER_NAME: EGGERMAN, THOMAS L

PROJECT_TERMS: accurate diagnosis;Address;Adult;Adverse effects;Applications Grants;Autologous Transplantation;Basic Science;biobank;Biological;Biological Assay;Biological Models;bronchial epithelium;Bronchoscopy;California;Caring;Caucasians;Cell secretion;Cells;Center Core Grants;Characteristics;Childhood;Chloride Channels;Chlorides;Chronic;Clinical;Clinical Research;Clinical Sciences;cohort;Collaborations;Conduct Clinical Trials;Core Facility;COVID-19;Cystic Fibrosis;cystic fibrosis patients;cystic fibrosis related diabetes;Cystic Fibrosis Transmembrane Conductance Regulator;database of Genotypes and Phenotypes;Databases;Dedications;Defect;demographics;Development;Diabetes Mellitus;DNA Sequence Alteration;Doctor of Philosophy;Duct (organ) structure;Duodenum;early onset;electronic medical record system;Endocrine;Endoscopy;Enteral;Epithelial Cells;Evaluation;Faculty;Fluids and Secretions;Fostering;Functional disorder;Funding;Future;Gases;gastrointestinal;Genetic Variation;Genotype;Goals;Grant;health care service;health disparity;Healthcare;Hispanic;Home;Hospitals;Human;imaging study;improved;Individual;individual patient;Institution;Institutional Review Boards;interest;Intestines;Islet Cell;Islets of Langerhans;Laboratories;Liver;Lung;lung health;Lung Transplantation;Magnetic Resonance Imaging;Measurement;Medical center;Medicine;Minority Groups;Molecular;multidisciplinary;Mutation;Nasal Epithelium;National Institute of Diabetes and Digestive and Kidney Diseases;news;Nose;Not Hispanic or Latino;Onset of illness;Oral Poliovirus Vaccine;organ on a chip;Organoids;Outcome;Pancreas;Patient Monitoring;patient population;Patients;Pediatric Hospitals;Pediatrics;personalized medicine;Phenotype;Physicians;Population;Positioning Attribute;Predisposition;preservation;Productivity;programs;pulmonary function;Pulmonary Surfactants;Pulmonology;Quality of Care;Quality of life;recruit;Rectum;Regulator Genes;Reporting;Research;Research Activity;research facility;Research Personnel;Resources;Rotavirus Vaccines;Sampling;Scientist;Services;Site;stem cell technology;stem cells;Structure;Subgroup;success;synergism;targeted treatment;Technology;therapy outcome;Time;Total Pancreatectomy;Training;Translational Research;Underrepresented Minority;United States;Well in self;Xenon


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Aging;Bioengineering;Genetics;Lung

ORG_CITY: PITTSBURGH

ORG_NAME: UNIVERSITY OF PITTSBURGH AT PITTSBURGH

ORG_STATE: PA

PI_NAMEs: KOENIGSHOFF, MELANIE  (contact)

PROJECT_TERMS: 3-Dimensional;Aging;Artificial Intelligence;beta-Galactosidase;Biological;Biological Markers;biomarker identification;Bleomycin;Body System;Calibration;cardiopulmonary system;Cell Aging;Cell Cycle Arrest;Cell Lineage;Cell Separation;Cells;cohort;Collaborations;Color;Computer Analysis;Data;Data Analyses;Detection;DNA Damage;Ensure;Environment;Epigenetic Process;Flow Cytometry;Functional disorder;Generations;Genes;Genomics;Heart;Heterogeneity;high resolution imaging;Human;Human body;human tissue;Image;image visualization;In Situ;Individual;Investigation;irradiation;life span;Lung;Maps;Measurement;Methods;mitochondrial dysfunction;Modality;Modeling;Molecular;Molecular Profiling;multimodal data;multiple omics;Network-based;neural network;novel;Ontology;Organ;Paraquat;Pathway interactions;Pattern;Phenotype;Prediction of Response to Therapy;Production;protein biomarkers;protein expression;Proteins;Proteomics;Quality Control;reconstruction;Reporting;Reproducibility;Research Design;Research Personnel;Resolution;response;Rotenone;Sampling;screening;secretory protein;senescence;senescent cell;senolytics;single-cell RNA sequencing;Slice;Sorting;Spatial Distribution;spatiotemporal;Stress;Technology;Telomere Shortening;Therapeutic;Tissue atlas;tissue mapping;Tissues;transcriptomics;tumorigenesis;Validation;Work

PROJECT_TITLE: Bio-Analysis-Core

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-D]


ORG_CITY: Los Angeles

ORG_NAME: UNIVERSITY OF SOUTHERN CALIFORNIA

ORG_STATE: CA

PI_NAMEs: KIRKPATRICK, MATTHEW GESNER (contact)

PROJECT_TERMS: abuse liability;Address;Adolescent;Behavior;Calibration;Characteristics;Chemicals;cognitive interview;Communities;computerized data processing;Creativeness;crowdsourcing;Data;Data Analyses;Data Collection;Databases;design verification;Development;Documentation;Electronic cigarette;Ensure;experimental study;Flavoring;flexibility;Fruit;Future;Goals;Grant;Hybrids;Ice;Internet;JUUL;Manuscripts;Marketing;Measures;meetings;Methodology;Nicotine;novel;Online Systems;Oral;Participant;Patient Self-Report;Pilot Projects;Policies;Population;Population Heterogeneity;Prevalence;Property;Psychometrics;public policy on tobacco;Readability;Regulation;Reporting;Research;Research Personnel;Research Project Grants;Respondent;Sales;Sampling;Science;Scientist;Sensory;Services;social media;Source;Stimulus;Surveys;symposium;Terminology;Testing;text searching;Time;Tobacco;tobacco advertising;tobacco products;tobacco regulatory science;Tobacco Surveillance;Tobacco use;tool;trend;vaping;Variant;web site;Work

PROJECT_TITLE: MMC


NIH_SPENDING_CATS: Cancer;Clinical Research;Genetic Testing;Genetics;Prostate Cancer;Urologic Diseases

ORG_CITY: NEW YORK

ORG_NAME: SLOAN-KETTERING INST CAN RESEARCH

ORG_STATE: NY

PHR: Narrative Analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTC) exist in very low proportion in liquid biopsy specimens, and therefore analyses of these samples are potentially heavily influenced by pre-analytical factors associated with acquisition and processing. We propose to expand our foundation-funded pilot study to evaluate effects of sample processing protocols on cfDNA and CTC analysis to further investigate effect of the patient-specific context. Results will inform the design of liquid biopsy-incorporated clinical trials by identifying optimal timing of blood collection to minimize effects of pre-analytical variables, and will be used to facilitate implementation of liquid biopsy testing in a clinical setting.

PI_NAMEs: ARCILA, MARIA E (contact);SCHER, HOWARD I

PROGRAM_OFFICER_NAME: AGRAWAL, LOKESH

PROJECT_TERMS: abiraterone;Address;Affect;Aliquot;androgen independent prostate cancer;Androgen Receptor;Anti-emetics;Atlases;Biological Assay;Biological Factors;Biological Markers;Biopsy Specimen;Blood;blood-based biomarker;cancer cell;Cancer Patient;Cell Count;cell free DNA;Cellular Assay;chemotherapy;Clinic;Clinical;clinical implementation;clinical practice;Clinical Trials;Clinical Trials Design;cohort;Collaborations;Collection;Communities;contextual factors;Data;Data Analyses;design;Detection;detection limit;Diagnosis;Disease;Early Diagnosis;Evaluation;Fasting;Foundations;Frequencies;Funding;Gene Frequency;genetic variant;Goals;implementation facilitation;individual patient;inhibitor;innovation;Institutional Review Boards;Knowledge;liquid biopsy;Malignant neoplasm of prostate;Malignant Neoplasms;member;Memorial Sloan-Kettering Cancer Center;Methods;Molecular;Molecular Profiling;Monitor;Mutation;Mutation Detection;Neoplasm Circulating Cells;Noise;Nuclear;Patients;Performance;Pilot Projects;Plasma;Point Mutation;practice setting;predictive marker;preservation;Procedures;Prognosis;Protocols documentation;Receptor Signaling;Relapse;Reporting;Reproducibility;Research;Resistance;response;Sampling;Science;Signal Transduction;Specificity;Steroids;taxane;Temperature;Testing;Time;Tube;tumor;Variant;Work

PROJECT_TITLE: Evaluation of the effect of patient-context factors and sample acquisition on the quality and analytical performance of cell-free DNA and circulating tumor cells profiling assays in prostate cancer pa


ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

FUNDING_MECHANISM: TRAINING, INSTITUTIONAL

NIH_SPENDING_CATS: Cancer;Prevention

ORG_CITY: SEATTLE

ORG_DEPT: ADMINISTRATION

ORG_NAME: UNIVERSITY OF WASHINGTON

ORG_STATE: WA

PHR: Narrative Cancer is the second leading cause of death in the United States. The Biobehavioral Cancer Prevention and Control Training Program (BCPT) prepares pre-doctoral and post-doctoral trainees for careers that will address the challenge of cancer prevention and control. The BCPT is a joint effort of departments in the Schools of Public Health, Medicine, Pharmacy, and Nursing at the University of Washington, the Fred Hutchinson Cancer Research Center, and affiliated institutions including the Seattle Cancer Care Alliance.

PI_NAMEs: HANNON, MARGARET A (contact)

PROGRAM_OFFICER_NAME: BOULANGER-ESPEUT, CORINNE A

PROJECT_TERMS: biobehavior;Cancer Control;cancer prevention;Training Programs

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Institutional Training and Education Study Section (F)[NCI-F]


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Neurosciences;Orphan Drug;Rare Diseases

ORG_CITY: ROCHESTER

ORG_NAME: MAYO CLINIC ROCHESTER

ORG_STATE: MN

PI_NAMEs: SARKARIA, JANN N. (contact)

PROJECT_TERMS: Animals;Brain Neoplasms;Clinical Trials;Collaborations;Communication;data sharing;Development;DNA Damage;drug distribution;Ensure;Evaluation;Fostering;Glioblastoma;Glioma;Goals;Human;industry partner;inhibitor;innovation;Institution;Lead;Leadership;Link;Logistics;Manuscripts;meetings;Mutagens;novel;novel therapeutic intervention;Office of Administrative Management;patient derived xenograft model;Pharmaceutical Preparations;pharmacokinetics and pharmacodynamics;Pharmacology;Pilot Projects;preclinical study;Quality Control;Recommendation;Reproducibility;Research Personnel;Resources;response;Services;Signal Transduction;Specimen;standard of care;Systems Analysis;Therapeutic;Therapy Evaluation;Tumor Biology

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Cystic Fibrosis;Lung;Precision Medicine;Rare Diseases;Stem Cell Research;Stem Cell Research - Embryonic - Human

PI_NAMEs: NAREN, ANJAPARAVANDA P (contact)

PROJECT_TERMS: Administrative Efficiency;Advisory Committees;Budgets;clinical care;Clinical Investigator;Collaborations;Core Facility;Cystic Fibrosis;cystic fibrosis patients;Cystic Fibrosis Transmembrane Conductance Regulator;Dedications;Environment;Fostering;Funding;gastrointestinal;Goals;Human Resources;implementation facilitation;improved;interest;Life;Lung;operation;outreach program;patient outreach;Personal Satisfaction;personalized medicine;Principal Investigator;programs;Quality of life;Research;Research Personnel;Services;Shapes;Site;Strategic Planning;translational scientist

PROJECT_TITLE: Personalized Cystic Fibrosis Therapy and Research Center


NIH_SPENDING_CATS: Cancer;Clinical Research;Lung;Lung Cancer;Precision Medicine;Prevention

ORG_CITY: BOSTON

ORG_NAME: DANA-FARBER CANCER INST

ORG_STATE: MA

PHR: Project Narrative The development of drug resistance limits the long term success of genotype directed therapies, including EGFR inhibitors in EGFR mutant lung cancer. By identifying and evaluating EGFR inhibitor based combination therapies in vitro and in vivo coupled with clinical trials of such combinations with these analyses of plasma derived DNA from on treatment lung cancer patients, the studies in this proposal aim to improve the outcome of EGFR mutant and other oncogenic subsets of lung cancer patients.

PI_NAMEs: JANNE, PASI A (contact)

PROGRAM_OFFICER_NAME: OLKHANUD, PUREVDORJ BALJINNYAM

PROJECT_TERMS: acquired drug resistance;anaplastic lymphoma kinase;Cancer Patient;cell free DNA;chemotherapy;Clinic;Clinical;Clinical Research;Clinical Trials;Combined Modality Therapy;Coupled;Development;DNA;drug resistance development;effective therapy;Epidermal Growth Factor Receptor;Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor;Genotype;Goals;improved;improved outcome;In Vitro;in vivo;Malignant neoplasm of lung;Malignant Neoplasms;mutant;next generation;Non-Small-Cell Lung Carcinoma;Oncogenic;Outcome;Pathway interactions;Patient-Focused Outcomes;Patients;Plasma;pre-clinical;Precision therapeutics;preclinical study;prevent;Process;Progression-Free Survivals;Receptor Inhibition;resistance mechanism;response;Signal Pathway;Signal Transduction;success;Toxic effect;Translating;tumor;Tyrosine Kinase Inhibitor

PROJECT_TITLE: Development of Combination Therapies to Delay/Prevent Acquired Drug Resistance


ADMINISTERING_IC: HS

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: AGENCY FOR HEALTHCARE RESEARCH AND QUALITY

ORG_CITY: HYATTSVILLE

ORG_NAME: MEDSTAR HEALTH RESEARCH INSTITUTE

ORG_STATE: MD

PHR: PROJECT NARRATIVE Diagnostic errors are a significant public health concern and the leading cause of harm due to medical care in the U.S.; yet research to date has principally focused on the clinician as the center of both the problems and the solutions. The Patient-Partnered Diagnostic Center of Excellence will shift this paradigm by convening diverse scientists and patients around research questions developed and prioritized by patients yielding patient- centered diagnostic safety solutions and reductions in diagnostic safety events. By providing clear evidence by measuring the problem (Safety I) and devising solutions to build diagnostic team resilience (Safety II), our Center has high potential to improve diagnostic safety for all patients in the U.S.

PI_NAMEs: GIARDINA, TRABER L;MILLER, KRISTEN ELIZABETH (contact);SMITH, KELLY MICHELLE

PROGRAM_OFFICER_NAME: COSBY, KAREN


ED_INST_TYPE: SCHOOLS OF MEDICINE

ORG_CITY: HERSHEY

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: PENNSYLVANIA STATE UNIV HERSHEY MED CTR

PHR: Narrative: The current COVID-19 pandemic is occurring in the midst of a public health crisis of opioid use disorder and overdose during pregnancy, and little is known about how these changes affect healthcare service use and outcomes. Thus, the aims of this study are to 1) examine how state policies related to maternal opioid use during pregnancy have changed in response to the COVID-19 pandemic, and 2) examine the effects of COVID-19-related changes in state policies regarding maternal opioid use on patterns of healthcare service use, maternal and child outcomes, and healthcare costs. By thoroughly examining the policy responses to the COVID-19 pandemic and linking these data to detailed claims data describing healthcare service use of women who use opioids during pregnancy and their newborns, we will be able to provide critical data to providers, insurers, health systems, and policymakers as they design treatment processes and policies to provide adequate pregnancy and substance use care to this vulnerable population to mitigate these two public health crises.

PI_NAMEs: CHUANG, CYNTHIA H;LESLIE, DOUGLAS L. (contact)

PROGRAM_OFFICER_NAME: CHEW, EMILY

PROJECT_TITLE: COVID-19, health systems and vulnerable populations: Policies affecting maternal opioid use during pregnancy

STUDY_SECTION: HSVR

STUDY_SECTION_NAME: Healthcare Systems and Values Research[HSVR]


NIH_SPENDING_CATS: Biomedical Imaging;Clinical Research;Cystic Fibrosis;Digestive Diseases;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Lung;Pediatric;Rare Diseases;Stem Cell Research;Stem Cell Research - Embryonic - Human

PI_NAMEs: BREWINGTON, JOHN JOSEPH (contact)

PROJECT_TERMS: Address;Age;Aging;Basic Science;Biological Markers;Biological Models;Biology;Biometry;Bronchoalveolar Lavage Fluid;Bronchoscopy;Caring;Caucasians;Cells;Childhood;chronic care model;Clinic;Clinical;clinical efficacy;clinical investigation;Clinical Research;Clinical Trials;cohort;Collaborations;Colorectal Surgery;Communities;Consultations;Coupled;Cystic Fibrosis;cystic fibrosis patients;cystic fibrosis related diabetes;Cystic Fibrosis Transmembrane Conductance Regulator;Data;Data Analyses;design;Disadvantaged;Disease;Disease Marker;Emerging Technologies;empowerment;Enrollment;Gastroenterology;gastrointestinal;Goals;Hispanic;Hispanic Populations;Human;Image;improved;indexing;Individual;Infant;Infrastructure;Institution;International;Intestinal Cancer;Intestinal Obstruction;Investigator-Initiated Research;Laboratories;Laboratory Finding;Link;Liquid substance;Liver diseases;Lung;lung imaging;Magnetic Resonance Imaging;Malnutrition;Measurement;Measures;Medical center;Monitor;Mutation;novel;Operative Surgical Procedures;organ on a chip;Pathology;Patient Care;Patients;Pediatric Hospitals;peer;personalized care;Persons;Physiological;Population;Population Heterogeneity;Process;programs;Pulmonology;Quality of life;rare variant;Regulator Genes;Research;Research Personnel;Research Project Grants;Research Support;Resolution;Resources;respiratory;response;Sampling;Serum;Source;Spirometry;Sputum;Standardization;Structure;Time;Tissues;tool;Translational Research;translational scientist;translational study;Underserved Population;United States;ventilation;Vision


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Neurosciences;Orphan Drug;Rare Diseases

PROJECT_TERMS: Animals;bench to bedside;Brain Neoplasms;Categories;Clinical;Clinical Research;Clinical Trials;Clinical Trials Network;Collaborations;combinatorial;Data;Data Analyses;Data Collection;data management;data quality;Decision Making;design;Development;Dose;drug candidate;drug distribution;Drug Kinetics;early phase clinical trial;efficacy evaluation;Evaluation;experimental study;Glioblastoma;Goals;Human;in vivo;innovation;Institution;Modeling;novel;novel therapeutic intervention;novel therapeutics;Operative Surgical Procedures;Patients;Pharmacodynamics;pharmacokinetics and pharmacodynamics;Pharmacology;Phase;Phase 0/1 Clinical Trial;preclinical evaluation;preclinical study;quality assurance;Regimen;research clinical testing;Research Personnel;Research Support;Safety;Sampling Studies;Schedule;Scientist;Statistical Data Interpretation;Testing;Therapeutic;Therapy Evaluation;Translations;treatment strategy;tumor;Work;Writing

PROJECT_TITLE: Therapy Evaluation Core


ED_INST_TYPE: SCHOOLS OF PHARMACY

ORG_CITY: ANN ARBOR

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: PROJECT NARRATIVE Unsafe e-prescription transactions, in which the prescribed medication ingredient, dosage form, or strength is not the medication dispensed, are a significant and largely unrecognized source of harm to patients. We will implement and evaluate a just-in-time feedback intervention, SAVE-Rx, that automatically identifies these dangerous medication safety events and actively communicates them to healthcare organizations for resolution. The overall objective of this proposal is to determine the effectiveness of the just-in-time feedback intervention on preventing patient harm using a large national sample of e-prescription transactions in the US.

PI_NAMEs: LESTER, COREY A (contact)

PROGRAM_OFFICER_NAME: SAMAD, FARZANA

PROJECT_TITLE: Preventing medication errors due to unsafe electronic prescription transactions with just-in-time feedback

STUDY_SECTION: HSQR

STUDY_SECTION_NAME: Healthcare Patient Safety and Quality Improvement Research[HSQR]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Breast Cancer;Cancer;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human;Women's Health Research

ORG_CITY: HOUSTON

ORG_NAME: METHODIST HOSPITAL RESEARCH INSTITUTE

ORG_STATE: TX

PHR: PROJECT NARRATIVE The objective of this project is to investigate the spatiotemporal dynamics, molecular crosstalk, and therapeutic targets underlying the interaction between breast cancer cells and their microenvironment niches in the bone.

PI_NAMEs: WONG, STEPHEN TC (contact);ZHANG, XIANG

PROGRAM_OFFICER_NAME: ZAMISCH, MONICA

PROJECT_TERMS: Adopted;Algorithms;Animal Model;Autocrine Communication;bioimaging;Bioinformatics;Biological;Biological Assay;Biology;bisphosphonate;Blood Vessels;bone;bone cell;Bone Marrow;Breast Cancer Cell;breast cancer metastasis;Breast Cancer Patient;cancer cell;Cancer Model;Cell Differentiation process;Cell Survival;cell type;Cells;Clinical;Clinical Research;clinical translation;Computational algorithm;Computer Assisted;Computer Models;CSPG4 gene;Data;design;Development;Diagnosis;Disease;drug efficacy;drug repurposing;Endothelial Cells;Excision;Exhibits;Foundations;Frequencies;Genetically Engineered Mouse;Goals;Homeostasis;Image;imaging capabilities;improved;In Situ;Indolent;Knowledge;Laboratories;laser capture microdissection;Lead;Lung;Lytic Metastatic Lesion;Malignant Breast Neoplasm;Malignant neoplasm of ovary;Malignant Neoplasms;Maps;Mediating;Mesenchymal Stem Cells;Metastatic Neoplasm to the Bone;Micrometastasis;Microscopic;Modeling;Molecular;Molecular Profiling;multiphoton microscopy;Neoplasm Metastasis;neoplastic cell;Osteogenesis;osteogenic;Osteolysis;Osteolytic;Outcome;Paracrine Communication;Patients;Pharmaceutical Preparations;Play;predictive modeling;prevent;Primary Neoplasm;Process;Proliferating;Quality of life;recruit;repaired;Resolution;response;Role;Series;Signal Pathway;Signal Transduction;spatiotemporal;Stromal Cells;success;Symptoms;Therapeutic;therapeutic target;tool;transcriptomic profiling;transcriptomics;Transforming Growth Factor beta;tumor;tumor microenvironment

PROJECT_TITLE: Spatiotemporal modeling of cancer-niche interactions in breast cancer bone metastasis


NIH_SPENDING_CATS: Cancer;Digestive Diseases;Orphan Drug;Pancreatic Cancer;Rare Diseases

ORG_CITY: OMAHA

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIVERSITY OF NEBRASKA MEDICAL CENTER

ORG_STATE: NE

PHR: PROJECT NARRATIVE Pancreas cancer kills essentially every patient it afflicts and, with a rising incidence and unabated mortality, it is now the third leading cause of cancer-related deaths in this country. We have developed genetically engineered animal models of pancreas cancer that have exposed unique points of vulnerability for the development of new treatments. We propose a systematic program of investigation to target distinct components of the stromal reaction in pancreas cancer as the basis for new treatment strategies against this highly resistant disease.

PI_NAMEs: HINGORANI, SUNIL R (contact)

PROGRAM_OFFICER_NAME: FORRY, SUZANNE L

PROJECT_TERMS: Ablation;Adhesions;Animal Model;Architecture;autocrine;Behavior;Biochemical;Biology;Biophysics;Blood Vessels;Cancer Etiology;cancer stem cell;CD44 Antigens;CD44 gene;Cell Adhesion Molecules;cell type;Cells;Cessation of life;Characteristics;Chemicals;Clinical;Clinical Trials;Complex;Country;design;Development;Diffusion;Disease;Disease Resistance;Drug Kinetics;Drug resistance;effector T cell;Engineering;Epithelial Cells;Epithelium;Evolution;Fostering;Generations;Genetic;Genetic Engineering;Glean;Glycosaminoglycans;Grant;Growth;Histopathology;HMMR gene;human disease;Hyaluronan;hypoperfusion;ICAM1 gene;Immune;Immunoglobulin Class Switching;Immunologics;Immunosuppression;improved;In Vitro;Incidence;interstitial;Investigation;Knowledge;Laboratories;Liquid substance;Malignant neoplasm of pancreas;Malignant Neoplasms;Mechanics;Mediating;Minority;Molecular;mortality;Mutate;Neoplasm Metastasis;neoplastic cell;Normal tissue morphology;novel;novel therapeutic intervention;novel therapeutics;Organ;pancreatic cancer cells;pancreatic cancer model;Pancreatic Ductal Adenocarcinoma;paracrine;Paracrine Communication;Pathogenesis;Patients;Penetration;Perfusion;Pharmaceutical Preparations;pharmacokinetics and pharmacodynamics;Physiology;pressure;prevent;Process;Prognosis;programs;Property;Proteins;Proteoglycan;Reaction;receptor;Resistance;Role;Sea;Series;Signal Pathway;Signal Transduction;Surface;Syndrome;T cell response;Testing;Therapeutic;Therapeutic Agents;therapy resistant;tumor;Water;Work

PROJECT_TITLE: OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER

STUDY_SECTION_NAME: Mechanisms of Cancer Therapeutics - 2 Study Section[MCT2]


ED_INST_TYPE: UNIVERSITY-WIDE

NIH_SPENDING_CATS: Bioengineering;Cancer

ORG_CITY: Princeton

ORG_NAME: PRINCETON UNIVERSITY

ORG_STATE: NJ

PHR: Metabolism plays a fundamental role in cancer growth, diagnosis, and treatment. I propose to develop improved mass spectrometry and isotope tracer technologies for quantitation of cancer metabolism, and to apply the technology to reveal tumor metabolic activity. The resulting understanding of metabolite levels and fluxes in cancer will open new therapeutic and diagnostic opportunities.

PI_NAMEs: LU, WENYUN  (contact)

PROGRAM_OFFICER_NAME: COUCH, JENNIFER A

PROJECT_TERMS: Acceleration;asparaginase;Award;Biopsy Specimen;Cancer Institute of New Jersey;Cells;Data;Development;Diagnosis;fluorodeoxyglucose positron emission tomography;Folic Acid Antagonists;Functional disorder;Goals;Growth;Immune;improved;in vivo;insight;Institution;Isotopes;Leadership;Malignant Neoplasms;mass spectrometric imaging;Mass Spectrum Analysis;Measurement;Metabolic;Metabolism;metabolomics;Methods;Modernization;Mus;novel;novel diagnostics;novel therapeutics;Oncogenes;Play;Positioning Attribute;Protocols documentation;Research;Resolution;Role;Selection for Treatments;Signal Transduction;Specialist;Technology;tool;Tracer;tumor;tumor metabolism;tumor microenvironment

PROJECT_TITLE: Revealing cancer metabolism via mass spectrometry and isotope tracers


NIH_SPENDING_CATS: Biotechnology;Clinical Research;Cystic Fibrosis;Digestive Diseases;Lung;Pediatric;Precision Medicine;Rare Diseases;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Embryonic - Human

PI_NAMEs: HELMRATH, MICHAEL A. (contact)

PROJECT_TERMS: Address;adult stem cell;Affect;Applications Grants;assay development;Bedside Testings;bench to bedside;Biological Assay;Biological Models;Biology;Cell Culture Techniques;Cell Line;Cells;Center Core Grants;Childhood;Clinical;clinical investigation;Clinical Trials;clinically relevant;Colon;Cystic Fibrosis;cystic fibrosis patients;Cystic Fibrosis Transmembrane Conductance Regulator;Data;Dedications;Development;directed differentiation;Disease;Dose;drug discovery;Duct (organ) structure;Embryo;Endoderm;Fluid Balance;Fluids and Secretions;Freezing;gastrointestinal;gastrointestinal transplantation;Genotype;Goals;Human;human induced pluripotent stem cells;human pluripotent stem cell;human stem cells;implantation;improved;In Vitro;in vivo;in vivo Model;individualized medicine;induced pluripotent stem cell;induced pluripotent stem cell technology;innovation;Interdisciplinary Study;interest;International;intestinal epithelium;Intestinal Fibrosis;intestine surgery;Intestines;Lung;Medical center;Membrane Proteins;Methodology;Methods;Microscopy;Modeling;Motility;multidisciplinary;mutant;Mutation;Myofibroblast;Names;National Institute of Diabetes and Digestive and Kidney Diseases;next generation;Nose;novel;Organ;Organogenesis;Organoids;Pancreas;Pancreatic duct;patient population;Patient-Focused Outcomes;Patients;Pattern;Pediatric Hospitals;personalized medicine;Phenotype;repository;Research;Research Personnel;Resources;Services;Small Intestines;sound;spheroids;stem cell derived tissues;stem cells;Techniques;Testing;Therapeutic;Therapeutic Intervention;three dimensional structure;Tissue Engineering;Tissues;tool;Training;Translating;Translational Research;Underrepresented Minority


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Clinical Research;Neurosciences;Orphan Drug;Rare Diseases

PI_NAMEs: ELMQUIST, WILLIAM  (contact)

PROJECT_TERMS: Address;Agar;ataxia telangiectasia mutated protein;Biochemical;Biological Assay;Biomedical Engineering;Blood - brain barrier anatomy;Brain;Brain Neoplasms;Cells;Clinical Trials;Collaborations;combinatorial;Data;design;Development;DNA Damage;Double Minutes;drug development;drug distribution;drug efficacy;Drug Exposure;Drug Kinetics;effective therapy;Evaluation;forest;Funding;Heterogeneity;Human;Imaging technology;Immunofluorescence Immunologic;Infiltration;inhibitor;innovation;Laboratories;Liquid Chromatography;mass spectrometric imaging;Massachusetts;Measures;mid-career faculty;Minnesota;Modeling;Mus;neurosurgery;Normal tissue morphology;novel therapeutics;Pathway interactions;Periodicity;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacodynamics;pharmacokinetics and pharmacodynamics;pharmacologic;Pharmacology;Pharmacy (field);Phase 0/1 Clinical Trial;phosphoproteomics;physical science;Process;professor;programs;Proteomics;Radiology Specialty;Recording of previous events;Regimen;Research;Research Personnel;response;Sampling;Schedule;Signal Pathway;Spatial Distribution;Systems Analysis;tandem mass spectrometry;Technology;Therapeutic;Therapeutic Agents;therapeutically effective;Therapy Evaluation;Tissue imaging;Tissue Sample;Tissues;TP53 gene;transcriptomics;tumor;Tumor Tissue;Tumor Volume;Universities;Validation;Work

PROJECT_TITLE: Pharmacology Core


ADMINISTERING_IC: HD

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Biotechnology;Congenital Structural Anomalies;Pediatric;Rare Diseases

ORG_CITY: OKLAHOMA CITY

ORG_DEPT: ANATOMY/CELL BIOLOGY

ORG_NAME: UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR

ORG_STATE: OK

PHR: Project Narrative Ciliopathy disorders are unified by their overlapping clinical features and underlying cilia-related biological mechanisms, combined affecting ~1/500 individuals. This project will identify how disease variants result in abnormal global ciliary protein content and if/how these variants contribute to aberrant trafficking. These experiments will lay the groundwork for determining the mechanisms of individual ciliopathies, and also a more comprehensive understanding of cilium biology.

PI_NAMEs: VAN DE WEGHE, JULIE CRAFT (contact)

PROGRAM_OFFICER_NAME: PARISI, MELISSA

PROJECT_TERMS: Active Biological Transport;Affect;Animal Model;Applications Grants;Bardet-Biedl Syndrome;base;Binding Proteins;Biological;Biology;Brain;career;Catalogs;Cell Cycle;cell fixing;Cell Line;Cell model;Cell Volumes;Cells;cellular imaging;Chronic;Cilia;ciliopathy;cilium biogenesis;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;Complement;Complex;Congenital Abnormality;Cues;Cytoplasm;Data;Dedications;Defect;Development;Developmental Delay Disorders;Disease;Distal;Embryo;Environment;Etiology;Exhibits;experimental study;Eye;Functional disorder;Future;G-Protein-Coupled Receptors;Genetic;Genome engineering;Goals;Health;Homeostasis;Human;human disease;Individual;innovation;Intellectual functioning disability;Joubert syndrome;Kidney;Knowledge;Laboratories;Libraries;Lipids;live cell microscopy;Liver;Mass Spectrum Analysis;Mediating;member;Membrane;Membrane Lipids;Mentors;Methods;Microtubules;Movement;Mutation;novel;null mutation;Organelles;Patients;Persons;Phase;Physiology;Polydactyly;Process;Protein Analysis;protein complex;Protein Dynamics;Protein Sortings;Protein translocation;protein transport;Proteins;Proteome;Proteomics;Protocols documentation;Research Personnel;Resources;Retinal Dystrophy;Ribosomes;Role;Signal Pathway;Signal Transduction;skeletal dysplasia;Skeleton;skills;Syndrome;System;targeted treatment;Techniques;trafficking;Variant;Work

PROJECT_TITLE: Integrating functional proteomics, genome engineering, and live-cell microscopy to the study of ciliopathies

STUDY_SECTION: NSS

STUDY_SECTION_NAME: NSS


NIH_SPENDING_CATS: Aging;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Complementary and Integrative Health;Dietary Supplements;Nutrition;Prevention;Prostate Cancer;Urologic Diseases

PHR: Narrative These early stage clinical trials take advantage of a niche prostate cancer patient cohort who have failed local “curative” therapies to address a significant unmet clinical need in a sizable recurrent cancer patient population who would otherwise soon face androgen deprivation therapy (ADT) through medical or surgical castration. Not only expensive, ADT also causes many serious and unpleasant side effects including sexual dysfunction/impotence, osteoporosis and bone fractures, mode swings, hot flashes, fatigue, loss of lean body mass, gynecomastia and anemia. In spite of multiple next-gen androgen and its receptor targeted drugs (e.g., abiraterone acetate, enzalutamide), DNA-repair drugs (PARP inhibitors) and microtubule targeting taxane drugs indicated for managing more advanced stage diseases, there is currently no FDA-approved modality before ADT to intercept or delay disease progression in the clinic practice. The trials will provide the first of its kind knowledge of safety and preliminary efficacy of an AGN herbal supplement against prostate cancer at therapeutic dosages, with mechanisms of action distinct from the currently approved drugs and more favorable safety profiles. The novel dose-exposure pharmacokinetics and pharmacogenetics information from these trials will be applicable to other patient populations to evaluate prevention and therapy of other cancers as well as other diseases since AGN supplements have been sold for memory health and pain killing for nearly 2 decades.

PI_NAMEs: JOSHI, MONIKA ;LU, JUNXUAN  (contact)

PROGRAM_OFFICER_NAME: RISCUTA, GABRIELA

PROJECT_TERMS: abiraterone;Acetates;Acute;Address;Adverse effects;androgen deprivation therapy;Androgen Receptor;Androgens;Anemia;Angelica;Animal Cancer Model;Animal Model;Animals;anti-cancer;Area Under Curve;Behavior;Biochemical;Biological Availability;Biological Markers;Blood;Cancer Burden;Cancer Patient;cancer recurrence;Cannabis;Caring;Castration;Cells;chemokine;Chronic;Clinic;Clinical;cohort;curative treatments;Cytochrome P450;cytokine;Data;Decision Making;design;Disease;Disease Progression;disorder prevention;DNA Repair;dosage;Dose;Drug Kinetics;Drug Targeting;efficacy evaluation;efficacy outcomes;enzalutamide;Face;Failure;Fatigue;FDA approved;Fish Oils;Food;Food Interactions;Fracture;Frequencies;Future;genetic signature;Goals;Gynecomastia;Half-Life;Health;Herbal supplement;Hot flushes;Human;human study;human subject;IL8 gene;Immune;Immunologic Markers;Immunologic Surveillance;Immunophenotyping;Immunosuppression;Impotence;in vivo;Inflammation;Inflammatory;Intercept;Knowledge;Koreans;lean body mass;Malignant neoplasm of prostate;Malignant Neoplasms;Measures;Medical Castration;Memory;Memory Loss;Messenger RNA;Metabolic;Microtubules;Modality;mortality;Mus;Nature;novel;Oncology;Oral;Osteoporosis;Outcome;Pain;patient population;Patients;Peripheral Blood Mononuclear Cell;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacogenetics;Phase;Phase I Clinical Trials;Phase I/II Trial;Plasma;Poly(ADP-ribose) Polymerase Inhibitor;prevent;Prevention;problem drinker;Prostate;prostate cancer model;Prostate Cancer therapy;Prostate-Specific Antigen;PSA level;Publishing;Radiation therapy;Radical Prostatectomy;Randomized, Controlled Trials;Raspberries;receptor;Recommendation;Recurrence;Reporting;response;Rodent;Safety;safety outcomes;Secondary Prevention;Secondary to;Sexual Dysfunction;side effect;Signal Transduction;soy;taxane;Tea;Testing;Therapeutic;Time;Tissues;Toxic effect

PROJECT_TITLE: Early clinial trials for Angelica herbal supplements for prostate cancer interception

STUDY_SECTION: CPSS

STUDY_SECTION_NAME: Cancer Prevention Study Section[CPSS]


NIH_SPENDING_CATS: Cystic Fibrosis;Lung;Pediatric;Rare Diseases;Stem Cell Research;Stem Cell Research - Embryonic - Human

PI_NAMEs: AMIN, RAOUF S. (contact)

PROJECT_TERMS: Academy;American;American Heart Association;Area;Arizona;Award;Basic Science;Cardiovascular Diseases;Cardiovascular system;Chest;Child;Clinic;Clinical;Collaborations;college;Communities;Cystic Fibrosis;Cystic Fibrosis Transmembrane Conductance Regulator;design;Development;Direct Costs;Endowment;epidemiology study;Extramural Activities;faculty mentor;Fostering;Foundations;Funding;Funding Agency;Goals;graduate student;Individual;innovation;Institution;Intention;interest;Investigation;Leadership;Lung;Lung Diseases;Medicine;member;Mentors;Names;National Heart, Lung, and Blood Institute;patient oriented research;pediatric department;Pediatric Hospitals;Pediatric Research;Pediatrics;Philadelphia;Physicians;Pilot Projects;Postdoctoral Fellow;Privatization;programs;Pulmonology;Research;Research Personnel;Research Project Grants;Resources;Scientific Advances and Accomplishments;Scientist;Sleep;Sleep Disorders;Societies;Study Section;Training;Training Programs;United States National Institutes of Health;Universities


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Clinical Research;Genetics;Neurosciences;Orphan Drug;Rare Diseases

PI_NAMEs: BINDRA, RANJIT  (contact)

PROJECT_TERMS: Address;adduct;Alkylating Agents;Alkylation;Apoptosis;ataxia telangiectasia mutated protein;ATR gene;base;Biological Markers;blood-brain barrier penetration;Brain;Brain Neoplasms;Cancer Therapy Evaluation Program;Carmustine;Cell Cycle;Cells;chemotherapy;Clinic;Clinical Trials;Clinical Trials Design;clinically relevant;Collaborations;Combined Modality Therapy;crosslink;cytotoxicity;Data;Defect;design;Disease;DNA;DNA analysis;DNA Damage;DNA Double Strand Break;DNA lesion;DNA Repair;DNA Repair Pathway;Dose;Double Strand Break Repair;Drug Kinetics;FDA approved;Futile Cycling;genotoxicity;Glioblastoma;Goals;improved;In Situ;In Vitro;in vivo;inhibitor;innovation;Lead;Lesion;Lomustine;Mediating;Methylation;Methyltransferase;Methyltransferase Gene;Mismatch Repair;Modeling;Molecular;Molecular Profiling;multidisciplinary;new combination therapies;Newly Diagnosed;Newly Diagnosed Disease;novel;novel therapeutic intervention;Operative Surgical Procedures;Pathway interactions;patient derived xenograft model;Patients;Pharmacologic Substance;Phase;Phase 0/1 Trial;phosphoproteomics;Phosphotransferases;promoter;Proteins;Radiation therapy;Recommendation;Recurrence;Recurrent disease;repaired;replication stress;Research;Resistance;response;safety testing;Sampling Studies;Signal Transduction;Site;standard of care;synergism;temozolomide;Therapeutic;Therapeutic Index;Tissues;Translations;tumor;Vertebral column;Work

PROJECT_TITLE: Novel DNA damage response inhibitor and alkylator combinations for GBM


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cancer;Chronic Liver Disease and Cirrhosis;Clinical Research;Digestive Diseases;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Liver Cancer;Liver Disease;Precision Medicine;Prevention;Racial and Ethnic Minority Health Research;Rare Diseases;Social Determinants of Health

ORG_CITY: CORAL GABLES

ORG_NAME: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE

ORG_STATE: FL

PHR: PROJECT NARRATIVE Hepatocellular carcinoma (HCC), also known as primary liver cancer, disproportionately affects minorities and the burden of this deadly disease has increased significantly. The proposed study will determine if genetic differences in African, European or Native American ancestry are responsible for the significant racial differences in liver cancer risk and survival, either directly or indirectly by interacting with other risk factors or social factors. Understanding which genetic features increase liver cancer risk or worsen survival could potentially improve our ability to (1) identify those people who are at highest risk and (2) develop screening and treatment strategies that are based on a person’s individualized risk.

PI_NAMEs: JONES, PATRICIA DENISE (contact)

PROGRAM_OFFICER_NAME: WALLACE, TIFFANY A

PROJECT_TERMS: Admixture;Advanced Malignant Neoplasm;Affect;African;ARID1A gene;Asian;Asian population;Award;Behavioral;biobank;Biological;Black Populations;Black race;Breast;Cancer Etiology;cancer risk;cancer survival;Case/Control Studies;Cessation of life;Characteristics;chromosomal location;chronic liver disease;Cirrhosis;Clinic;Clinical Data;clinical epidemiology;clinical phenotype;cohort;Colon;Communities;CTNNB1 gene;Data;Data Analyses;Data Set;Diagnosis;Disease;disorder control;Disparity;DNA Sequence Alteration;Educational workshop;Enrollment;Epidemiologic Factors;ethnic minority;European;experience;Fibrosis;Financial Hardship;Florida;Foundations;Funding;Future;gene environment interaction;Genes;Genetic;genetic analysis;Genetic Determinism;genetic epidemiology;Genetic study;Genetic Variation;Genome;Genomics;Genotype;Goals;Haplotypes;hazard;health care disparity;health disparity;Hepatobiliary;hepatobiliary cancer;high risk;Hispanic;Hispanic Populations;improved;Individual;Inflammation;innovation;Institution;Internships;K-Series Research Career Programs;Knowledge;Laboratories;Link;Liver diseases;Malignant neoplasm of liver;Malignant Neoplasms;Mentors;Mentorship;Minority;Modeling;mortality;multidisciplinary;Mutate;Native American Ancestry;Native Americans;Not Hispanic or Latino;novel;Outcome;Participant;Pathway interactions;patient oriented;patient oriented research;Patient-Focused Outcomes;Patients;Performance;personalized approach;Persons;Phenotype;phenotypic data;Physicians;Population;Population Heterogeneity;precision medicine;predictive modeling;Prevalence;Primary carcinoma of the liver cells;Primary Malignant Neoplasm of Liver;Prognosis;prognostication;progression risk;Prospective cohort;Prostate;Race;racial difference;racial disparity;racial minority;Research;Research Personnel;Risk;Risk Factors;risk prediction model;risk stratification;risk variant;Scientist;screening;skills;social determinants;social factors;social health determinants;socioeconomic diversity;Survival Analysis;survival disparity;survival prediction;The Cancer Genome Atlas;Time;tool;TP53 gene;Training;Training Activity;treatment strategy;Tumor Biology;United States;United States National Institutes of Health

PROJECT_TITLE: The Impact of Genetic Ancestry on Racial Disparities in Hepatocellular Carcinoma Risk and Mortality

STUDY_SECTION_NAME: Career Development Study Section (J)[NCI-J]


ADMINISTERING_IC: AA

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Behavioral and Social Science;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Cost Effectiveness Research;Dissemination and Implementation Research;HIV/AIDS;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Infectious Diseases;Mental Health;Networking and Information Technology R&D (NITRD);Prevention;Racial and Ethnic Minority Health Research;Screening and Brief Intervention for Substance Misuse;Social Determinants of Health;Substance Misuse;Telehealth;Violence Against Women;Violence Research;Women's Health Research

ORG_NAME: COLUMBIA UNIVERSITY HEALTH SCIENCES

PHR: The proposed study intervention represents the first PrEP mHealth tool that synergistically addresses intimate partner violence and alcohol-related barriers to HIV pre-exposure prophylaxis (PrEP) with novel peer navigation and telemedicine components that are designed to increase PrEP initiation and adherence among women in community supervision programs (CSPs) in New York City. This study addresses a key priority of the National HIV strategy to reduce HIV disparities and increase (PrEP) uptake among cis-gendered women. Advancing an effective PrEP intervention for women in CSPs, who are disproportionately Black and Latinx, holds promise for reducing HIV disparities.

PI_NAMEs: DASGUPTA, ANINDITA  (contact);GILBERT, LOUISA

PROGRAM_OFFICER_NAME: FREEMAN, ROBERT

PROJECT_TERMS: Address;Adherence;Adoption;Age;AIDS prevention;alcohol screening and brief intervention;Alcohols;Area;Biological Assay;Black race;black women;cis-female;Communities;community organizations;comparative cost effectiveness;comparative effectiveness;contextual factors;cost effectiveness;cost efficient;Decision Making;design;digital;disparities in women;Drug Legislation;Education;Effectiveness;effectiveness testing;effectiveness trial;effectiveness-implementation RCT;effectiveness/implementation trial;Eligibility Determination;Enrollment;Ethnic Origin;evidence base;Female;follow-up;Fortune;Gender;General Population;Goals;hazardous drinking;health equity;health inequalities;Heavy Drinking;high risk;high risk population;HIV;HIV disparities;HIV Infections;HIV risk;Housing;hybrid type 1 trial;Hybrids;implementation framework;implementation research;Imprisonment;incremental cost;Individual;innovation;Intervention;Intervention Studies;intimate partner violence;Latinx;Legal system;literacy;Measures;Medical;Medical Records;mHealth;mhealth interventions;Multiple Partners;New York City;Not Hispanic or Latino;novel;Outcome;Outcome Study;parole;Participant;partner violence;Patient Self-Report;peer;Population;post intervention;Practical Robust Implementation and Sustainability Model;pre-exposure prophylaxis;prevent;Prevention strategy;primary outcome;probation;Process;programs;Race;racial health disparity;Randomized;Randomized, Controlled Trials;Reach, Effectiveness, Adoption, Implementation, and Maintenance;recidivism;Recording of previous events;Reduce health disparities;Reporting;Research Personnel;Risk Behaviors;Safety;scale up;screening, brief intervention, referral, and treatment;secondary outcome;Severities;sex;Sex Orientation;social stigma;Societies;Subgroup;Substance Use Disorder;Supervision;syndemic;Telemedicine;Tenofovir;Testing;tool;Unsafe Sex;uptake;Urine;Violence;violence exposure;White Women;Woman

PROJECT_TITLE: An effectiveness trial of WINGS+PrEP: a syndemic mHealth intervention to increase PrEP uptake among women impacted by heavy alcohol use and partner violence in the criminal legal system


ADMINISTERING_IC: HG

IC_NAME: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

NIH_SPENDING_CATS: Bioengineering;Biotechnology;Data Science;Genetics;Human Genome;Kidney Disease;Networking and Information Technology R&D (NITRD)

ORG_CITY: MADISON

ORG_DEPT: BIOSTATISTICS & OTHER MATH SCI

ORG_NAME: UNIVERSITY OF WISCONSIN-MADISON

ORG_STATE: WI

PHR: PROJECT NARRATIVE: Systematic comparison of gene regulatory networks across species is essential for better understanding of the evolution of normal and disease traits. This project will develop and apply novel computational tools for single cell omic datasets from multiple species to enable identification and characterization of cell types and their underlying gene regulatory networks. This project will also generate and analyze a novel multi-species multi- omic single cell dataset for kidney that will provide fundamental insights into normal kidney function and diseases.

PI_NAMEs: ROY, SUSHMITA  (contact)

PROGRAM_OFFICER_NAME: FUFA, TEMESGEN D

PROJECT_TERMS: Acute;Address;ATAC-seq;Automobile Driving;Awareness;Biological;Biology;Brain;cell fate specification;Cell Lineage;Cell Nucleus;cell type;Cells;Chromosome Mapping;CISH gene;Clinical;Clustered Regularly Interspaced Short Palindromic Repeats;comparative;Comparative Study;computerized tools;Computing Methodologies;computing resources;Data;Data Analyses;Data Set;Development;Disease;Elements;Evolution;Excision;Exhibits;Family suidae;functional genomics;gene conservation;Gene Expression;Gene Expression Profile;Gene Expression Regulation;gene regulatory network;Genes;genetic regulatory protein;Genomic Segment;Growth;Heterogeneity;Human;Individual;infancy;innovation;insight;Kidney;Kidney Diseases;Learning;machine learning method;Measurement;Measures;Medicine;Methods;Modeling;Molecular;multiple datasets;multiple omics;multitask;Mus;Nephrectomy;novel;Organ;Pathologic Processes;Pathway Analysis;Patients;Pattern;Phenotype;Phylogenetic Analysis;Phylogeny;Physiology;Play;Population;Primates;Process;programs;Property;Proteins;Publishing;Rattus;Renal function;Research Design;Research Personnel;Resolution;Retina;Rodent;Role;Sampling;single cell technology;single-cell RNA sequencing;Small Interfering RNA;Software Tools;Source;spatiotemporal;Specific qualifier value;Specificity;Structure;System;Technology;Testing;Time;Tissues;tool;trait;transcription factor;Transgenes;trend;validation studies;Work

PROJECT_TITLE: Leveraging multi-species single cell omic datasets to study the evolution of cell type-specific gene regulatory networks

STUDY_SECTION: GVE

STUDY_SECTION_NAME: Genetic Variation and Evolution Study Section[GVE]


NIH_SPENDING_CATS: Brain Cancer;Brain Disorders;Cancer;Clinical Research;Genetics;Immunotherapy;Neurosciences;Rare Diseases

ORG_CITY: NEW HAVEN

ORG_DEPT: PEDIATRICS

ORG_NAME: YALE UNIVERSITY

ORG_STATE: CT

PHR: PROJECT NARRATIVE Immune checkpoint inhibitors have, thus far, been ineffective in the treatment of gliomas, largely due to the immunologically “cold” microenvironment and a low number of neoantigens. Our group recently discovered that IDH1/2 mutations, which are common in gliomas, induce homologous recombination defects and confer sensitivity to DNA damage response inhibitors. The goal of this project is to uncover strategies to exploit IDH1/2-induced DNA repair defects with DNA damage response inhibitors to induce synthetic lethality and generate an immunologically favorable tumor microenvironment thereby improving the response to immune checkpoint inhibition.

PI_NAMEs: VASQUEZ, JUAN C (contact)

PROJECT_TERMS: Advisory Committees;anti-PD-1;anti-PD1 therapy;ATR gene;BRCA deficient;Cancer Biology;cancer cell;cancer therapy;carcinogenesis;Cell Cycle Progression;Cell Physiology;Cellular biology;checkpoint inhibition;Citric Acid Cycle;clinical efficacy;Clinical Trials Design;comparative efficacy;Computational Biology;cytotoxicity;Defect;Dioxygenases;DNA;DNA Damage;DNA Double Strand Break;DNA Repair;DNA Repair Pathway;Double Strand Break Repair;early phase clinical trial;Evaluation;experience;experimental study;Family;Fumarates;Funding;Genes;Genetic;Genomic Instability;Glioblastoma;Glioma;Goals;Grant;Histones;homologous recombination;Hypermethylation;Immune;immune activation;immune checkpoint blockade;Immune checkpoint inhibitor;Immune Targeting;Immunocompetent;Immunocompromised Host;immunogenic;immunogenic cell death;immunogenicity;Immunologics;Immunooncology;immunoregulation;Immunotherapy;improved;In Vitro;in vivo;Inherited;inhibitor;innate immune pathways;Interferons;Isocitrate Dehydrogenase;kinase inhibitor;knockout gene;Laboratories;Laboratory Research;Link;Literature;Lysine;Malignant Neoplasms;Mediating;medical schools;member;Mentors;Mentorship;metaplastic cell transformation;Methods;Methylation;Modeling;Molecular Biology;Morbidity - disease rate;mouse model;multidisciplinary;Mus;mutant;Mutation;Nature;neoantigens;neuroimmunology;novel;Pathway interactions;Pediatrics;Phenotype;Phosphotransferases;Physicians;Poly(ADP-ribose) Polymerase Inhibitor;Poly(ADP-ribose) Polymerases;pre-clinical;preclinical study;preclinical trial;Production;professor;programmed cell death ligand 1;programs;Publishing;recruit;repaired;Reporting;Research;Research Personnel;Research Project Grants;Research Training;Resources;response;Scientist;Series;Signal Transduction;Site;skills;small molecule;Stimulator of Interferon Genes;success;Succinates;symposium;synergism;T-Cell Depletion;Testing;Time;Training Programs;translational medicine;Translational Research;Triplet Multiple Birth;tumor;Tumor Immunity;tumor immunology;tumor microenvironment;tumor-immune system interactions;Up-Regulation;Yale Cancer Center

PROJECT_TITLE: Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomas


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Clinical Research;Genetics;Neurosciences;Orphan Drug;Radiation Oncology;Rare Diseases

PI_NAMEs: SARKARIA, JANN N. (contact)

PROJECT_TERMS: Animals;Apoptosis;Apoptotic;Blood - brain barrier anatomy;Brain;Brain Neoplasms;cancer cell;cancer therapy;CDKN2A gene;Cell Cycle Arrest;Cellular Stress;Chemotherapy and/or radiation;Clinical;clinical development;Code;Collaborations;combinatorial;Combined Modality Therapy;conventional therapy;Data;Digit structure;DNA Damage;DNA Repair;Dose;Double Minutes;drug distribution;Drug Kinetics;Drug Targeting;Feedback;first-in-human;fractionated radiation;Genes;Genetic Transcription;genome integrity;Genomic Instability;Genotoxic Stress;genotoxicity;Glioblastoma;Half-Life;Heel;improved outcome;In Vitro;in vivo;inhibitor;inhibitor therapy;innovation;Isocitrate Dehydrogenase;kinase inhibitor;Link;Malignant Neoplasms;Mediating;MGMT gene;Modeling;Mus;Mutation;nanomolar;Newly Diagnosed;novel therapeutic intervention;Pathway interactions;patient derived xenograft model;Patients;Pharmaceutical Preparations;pharmacodynamic biomarker;Pharmacodynamics;pharmacokinetics and pharmacodynamics;pharmacologic;Phase;Phase 0 Trial;Phase I Clinical Trials;Plasma;pre-clinical;prevent;Radiation;Radiation therapy;Regimen;Regulation;Resistance;response;restoration;Sampling Studies;senescence;Series;Signal Pathway;Signal Transduction;small molecule;small molecule inhibitor;Structure;success;temozolomide;Testing;Therapeutic;therapeutic target;Tissues;TP53 gene;Transcriptional Regulation;Treatment Efficacy;tumor;Tumor Suppressor Proteins;tumorigenesis;Ubiquitination

PROJECT_TITLE: MDM2 inhibitor therapy for TP53 wild-type GBM


ED_INST_TYPE: HOSPITALS

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Clinical Research;Clinical Trials and Supportive Activities;Digestive Diseases;Liver Cancer;Liver Disease;Precision Medicine;Rare Diseases

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_NAME: UNIVERSITY OF TX MD ANDERSON CAN CTR

PHR: PROJECT NARRATIVE: Quantitative PET Imaging of Hepatocellular Carcinoma Clinical decisions regarding the treatment of patients with hepatocellular carcinoma (HCC) remain largely guided by conventional, anatomical imaging modalities. This application proposes the clinical evaluation of an innovative PET imaging tracer that may personalize decision making in the care of patients with HCC.

PI_NAMEs: MANNING, HENRY CHARLES (contact)

PROGRAM_OFFICER_NAME: DARDZINSKI, BERNARD JOSEPH

PROJECT_TERMS: Acetates;American Cancer Society;anatomic imaging;Asia;Benign;Biology;Brain;Breast;Cessation of life;Cirrhosis;Clinical;clinical imaging;Clinical Management;Clinical Oncology;Clinical Research;Clinical Trials;cohort;Colon;Colon Carcinoma;comorbidity;Data;Data Analyses;Decision Making;Detection;Diagnosis;Diagnostic;Diagnostic Imaging;Diagnostic tests;Discrimination;Effectiveness;Eligibility Determination;Evaluation;Excision;Exhibits;Feasibility Studies;fluorodeoxyglucose;Future;Glutamates;Glutamic Acid;Goals;Healthcare;Human;Image;imaging approach;Imaging Device;imaging modality;imaging study;immunohistochemical markers;improved;Incidence;Individual;innovation;insight;Intervention;Lesion;Liver;Liver neoplasms;liver transplantation;Lung;Magnetic Resonance Imaging;Malignant - descriptor;Malignant Breast Neoplasm;Malignant neoplasm of brain;Malignant neoplasm of liver;Malignant neoplasm of lung;Malignant Neoplasms;Measures;metabolic profile;Methodology;Methods;Modality;Molecular;molecular imaging;non-invasive imaging;novel;novel diagnostics;Oncology;Operative Surgical Procedures;Pathology;Patient Care;Patient Schedules;Patient Selection;Patients;Pattern;personalized care;personalized decision;pharmacokinetic model;Pilot Projects;Positron-Emission Tomography;precision oncology;prevent;Primary carcinoma of the liver cells;Primary Malignant Neoplasm of Liver;Primary Neoplasm;prospective;Protocols documentation;quantitative imaging;Randomized;research clinical testing;Role;Safety;Schedule;Sensitivity and Specificity;Specimen;Staging;standard of care;Standardization;statistics;Testing;tool;Tracer;Transplant Recipients;tumor;tumor behavior;tumor metabolism;Tumor Tissue;United States;uptake;X-Ray Computed Tomography

PROJECT_TITLE: Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)

STUDY_SECTION: CTIS

STUDY_SECTION_NAME: Clinical Translational Imaging Science Study Section[CTIS]


ADMINISTERING_IC: EY

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Clinical Research;Eye Disease and Disorders of Vision;Neurosciences

ORG_DEPT: PSYCHOLOGY

ORG_NAME: NEW YORK UNIVERSITY

PHR: PROJECT NARRATIVE The proposed research is relevant to public health because advancement in our understanding of the mechanisms by which the brain encodes and maintains working memory representations in the normal brain is necessary to illuminate the mechanisms that could go awry in the pathological brain. Specifically, the proposed research is relevant to NIH’s mission because is expected to advance a stronger theoretical framework within which clinical researchers can develop strategies for the diagnosis and treatment of psychiatric and neurologic disorders.

PI_NAMEs: CURTIS, CLAYTON E (contact)

PROGRAM_OFFICER_NAME: WIGGS, CHERI

PROJECT_TERMS: Area;Behavior;Brain;Clinical;Code;Cognition;cognitive function;Cognitive remediation;Data;Data Analytics;Decision Making;Diagnosis;dimension reduction;distraction;Elderly;Evolution;experimental study;Functional disorder;Goals;Human;Impaired cognition;innovation;insight;Knowledge;Learning;Left;Maps;Measures;Memory;Memory impairment;memory retention;Mental disorders;Mission;Modeling;Motion;Nature;Nervous System Disorder;neural;neural model;neural patterning;neuroimaging;Neurologic;neuromechanism;Neurosciences Research;novel;Outcome;Pathologic;Pattern;Population;Population Dynamics;Property;Psychiatric therapeutic procedure;Public Health;Reading;receptive field;Research;Research Personnel;Resistance;retinal stimulation;retinotopic;Sensory;Short-Term Memory;stem;Stimulus;success;Symptoms;Techniques;Testing;theories;Time;United States National Institutes of Health;Visual;Visual Cortex;visual stimulus;Visualization;Work

PROJECT_TITLE: The Nature of Working Memory Representations


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Genetics;Hematology;Infectious Diseases;Sepsis

ORG_CITY: Columbus

ORG_DEPT: SURGERY

ORG_NAME: OHIO STATE UNIVERSITY

PHR: (aka Project Narrative) Septic survivors exhibit long-term immunologic dysfunction associated with higher rates of disability, depression, subsequent infections, and all-cause mortalities; however, our understanding of the regulation of these responses and their impact on disease is lacking. This proposal will integrate mechanistic in vitro studies with human data and quality of life outcomes measures to provide an indepth assessment of the systemic epigenetic events that occur during sepsis and how their regulation of the post-septic immunosuppressive response effects the immunologic and functional outcomes of patients. The proposal has the potential to provide fundamental insight into disease regulation and novel therapeutics for the treatment of post-sepsis immunosuppression.

PI_NAMEs: WISLER, JON R (contact)

PROGRAM_OFFICER_NAME: ZHAO, XIAOLI

PROJECT_TERMS: Area;biopsychosocial;Clinical;clinical effect;Clinical Investigator Award;Coupled;Couples;Critical Care;Data;Diagnosis;direct application;disability;Disease;DNA Methylation;DNA Modification Methylases;Epigenetic Process;epigenetic regulation;Event;Exhibits;functional decline;functional outcomes;Gene Silencing;human data;immune function;Immune System Diseases;Immunologics;Immunosuppression;improved;In Vitro;in vivo;Infection;innate immune function;insight;Intervention;Investigation;Knowledge;Laboratories;Long-Term Effects;Mediating;Meditation;Mental Depression;Methylation;Molecular;mortality;novel therapeutics;Operative Surgical Procedures;Outcome;Outcome Measure;Patient-Focused Outcomes;Patients;pharmacologic;Phase;Process;Productivity;professor;programs;psychosocial outcome;Quality of life;Recovery;Regulation;Research;Research Personnel;response;restoration;Sepsis;septic;skills;Survivors;survivorship;synergism;therapeutic evaluation;Time;Trauma;Treatment/Psychosocial Effects;United States National Institutes of Health

PROJECT_TITLE: Analyzing the long-term effects of DNA methylation meditated immunosuppression following sepsis

STUDY_SECTION: MRAD

STUDY_SECTION_NAME: Maximizing Investigators' Research Award - D Study Section[MRAD]


PI_NAMEs: PARNEY, IAN F (contact)

PROJECT_TERMS: Administrative Coordination;Adult Glioblastoma;Animal Model;anti-cancer research;Automobile Driving;biobank;Biological Specimen Banks;biomedical referral center;Biometry;Brain Neoplasms;Cancer Center;chemotherapy;Clinic;Clinical;Clinical Research;clinical translation;Clinical Trials;Clinical Trials Cooperative Group;Collaborations;Communication;Communities;Data;Data Collection;Data Coordinating Center;data management;data quality;design;Development;drug development;electronic data;experience;FDA approved;Foundations;Funding;Glioblastoma;Glioma;Housing;Human;Individual;Industry;Infrastructure;innovation;Institution;instrument;Leadership;Maintenance;Malignant - descriptor;Malignant Neoplasms;Mayo Clinic Cancer Center;meetings;member;Modeling;Multi-Institutional Clinical Trial;neuro-oncology;neuropathology;novel therapeutics;Oncology;Operative Surgical Procedures;Pharmacologic Substance;Phase;Positioning Attribute;pre-clinical;preclinical development;Primary Brain Neoplasms;Procedures;Process;Prognosis;programs;quality assurance;Quality Control;Radiation;Recording of previous events;Research;Research Infrastructure;Research Personnel;Resources;response;Role;Specimen;Standardization;statistics;Structure;success;Testing;Therapeutic;Therapeutic Agents;Tissue Banks;Translational Research;web site;Work

PROJECT_TITLE: Network Coordinating Center


NIH_SPENDING_CATS: Aging

ORG_CITY: DURHAM

ORG_NAME: DUKE UNIVERSITY

ORG_STATE: NC

PHR: PROJECT NARRATIVE: The Duke Center for Aging Postdoctoral Research Training Program (RTP) trains scientists with rich potential for leadership in gerontology and/or geriatrics. It covers aging from an interdisciplinary biopsychosocial perspective and is highly relevant to public health concerns. This integrated translational approach to research in aging drives the generation of new investigators and new knowledge that can be applied to promote quality of life for older adults.

PI_NAMEs: COHEN, HARVEY JAY (contact)

PROGRAM_OFFICER_NAME: TORRES, DELANY

PROJECT_TERMS: Aging;Behavior;Physiology

PROJECT_TITLE: Behavior and Physiology in Aging


ADMINISTERING_IC: AI

ED_INST_TYPE: ORGANIZED RESEARCH UNITS

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

NIH_SPENDING_CATS: Infectious Diseases

ORG_DEPT: MISCELLANEOUS

ORG_NAME: COLUMBIA UNIV NEW YORK MORNINGSIDE

PHR: Project Narrative Marginal zone B cells are key players in defending against bacteria and viruses that enter the circulation; generating a reservoir of antibodies against common pathogens, and regulating tolerance to our own proteins and lipids. A quantitative understanding of their homeostasis will provide unparalleled insights into determinants that shape their pool size and clonal repertoire, across our lifespan and during immune responses. Leveraging or manipulating these determinants to modulate antibody-mediated protection – for example, to boost the efficacy of vaccines or potency of immune-regulative treatments – will have direct relevance to human health, guiding the development of therapeutics against systemic infections, immunodeficiencies, and autoimmunity.

PI_NAMEs: RANE, SANKET  (contact)

PROGRAM_OFFICER_NAME: GONDRE-LEWIS, TIMOTHY A

PROJECT_TERMS: adaptive immunity;Adopted;Adult;Age;Antibodies;Antibody-mediated protection;Antigens;Autoimmune;Autoimmunity;B cell differentiation;B-Cell Activation;B-Cell Antigen Receptor;B-Lymphocyte Subsets;B-Lymphocytes;Bacteria;Bacterial Infections;Bayesian Analysis;Blood-Borne Pathogens;Bone Marrow;cell age;Cell Compartmentation;Cell Count;Cell division;Cell Maintenance;Cell Ontogeny;Cells;Cessation of life;Chimera organism;Circulation;Clinical;Complex;computational pipelines;congenic;Coupled;Data;Dedications;density;Development;Elderly;Emigrant;Encapsulated;Environment;experimental study;Frequencies;Gatekeeping;Generations;Growth;Health;Heterogeneity;Homeostasis;Human;humoral immunity deficiency;Immune;immune activation;Immune response;Immune system;immunodeficiency;immunogenic;Immunoglobulin M;Impairment;Infant;Infiltration;insight;kinetic model;Kinetics;Life;life span;Link;Lipids;Lymphatic;Lymphocyte;Maintenance;Malignant - descriptor;Maps;mathematical model;Mathematics;Mature B-Lymphocyte;Measures;Mediating;Modeling;mortality;Mouse Strains;Mus;Mutation;Natural Immunity;neonate;novel;pathogen;Pathology;Pathway interactions;Patients;Peripheral;permissiveness;Phylogenetic Analysis;Play;Population;Positioning Attribute;Predisposition;Process;Proliferating;Proteins;quorum sensing;Regulation;Reporter;Reporter Genes;residence;response;restoration;self-renewal;Sepsis;Shapes;Signal Transduction;Splenectomy;System;Systemic infection;T-Independent Antigens;Testing;therapeutic development;therapeutic target;therapy development;Time;tool;transcriptomics;Trees;vaccine efficacy;Variant;Virus

PROJECT_TITLE: Integrative approaches defining the ontogeny, maintenance, and immune response dynamics of marginal-zone B cells

STUDY_SECTION: MABS

STUDY_SECTION_NAME: Modeling and Analysis of Biological Systems Study Section[MABS]


ORG_CITY: SAN FRANCISCO

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PHR: Project Narrative This competitive renewal application of a Ruth L. Kirschstein National Research Service Award Postdoctoral Research Training Grant that has the overall goal of training physicians (MD or MD/PhD) for independent research careers investigating the etiology, pathogenesis, and treatment of pediatric cancer. We believe that the outstanding research faculty, institutional resources, educational programs, and pool of highly qualified trainees at UCSF result in an outstanding environment for achieving this goal.

PI_NAMEs: SWEET-CORDERO, ERIC ALEJANDRO (contact)

PROGRAM_OFFICER_NAME: DAMICO, MARK W

PROJECT_TERMS: Malignant Childhood Neoplasm;Research Training

PROJECT_TITLE: Research Training in Childhood Cancer


ORG_NAME: MEDSTAR HEALTH RESEARCH INSTITUTE

PHR: PROJECT NARRATIVE This project is relevant to public health because it applies system engineering and human factors techniques to identify and address patient safety issues associated with telehealth. The safety learning laboratory will identify prominent patient safety issues and develop solutions to address these issues using an iterative process. Solutions will be implemented and evaluated for their effectiveness at improving patient safety.

PI_NAMEs: BOOKER, ETHAN A.;RATWANI, RAJ M (contact)

PROGRAM_OFFICER_NAME: HAUGSTETTER, MONIKA

PROJECT_TITLE: Safe and Equitable Telehealth for Chronic Conditions (SafE-T C2) Learning Laboratory


NIH_SPENDING_CATS: Cancer;Cancer Genomics;Childhood Leukemia;Clinical Research;Genetics;Hematology;Human Genome;Orphan Drug;Pediatric;Pediatric Cancer;Precision Medicine;Rare Diseases

ORG_CITY: MEMPHIS

ORG_NAME: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

ORG_STATE: TN

PHR: PROJECT NARRATIVE Clonal heterogeneity and clonal selection contribute to drug resistance and disease recurrence in children with relapsed T-cell acute lymphoblastic leukemia (T-ALL) who have a dismal survival rate of < 25%. By single-cell approaches, we discovered the intra-leukemia heterogeneity associated with T-cell development and drug sensitivity. This project will identify clonal therapy by combining drugs that target major clones and rare ones contributing to disease relapse to improve the outcomes for children with T-ALL.

PI_NAMEs: YANG, JUN J.;YU, JIYANG  (contact)

PROJECT_TERMS: Acute Lymphocytic Leukemia;Acute T Cell Leukemia;Algorithms;Automobile Driving;B-Cell Acute Lymphoblastic Leukemia;B-Lymphocytes;BCL2 gene;burden of illness;cancer cell;Cancer Etiology;Cell Communication;cell fate specification;Cell Lineage;Cell Maturation;Cells;Cessation of life;chemotherapy;Child;Childhood;Childhood Precursor T Lymphoblastic Leukemia;Clinical Trials;Clonality;Clone Cells;Combination Drug Therapy;Communication;CRISPR screen;Dasatinib;Data;Dependence;Development;Developmental Process;Disease;Disease Outcome;Drug Combinations;Drug resistance;Drug Screening;drug sensitivity;Drug Targeting;Etiology;Exhibits;Genomics;Heterogeneity;improved;improved outcome;In Vitro;in vivo;Inferior;inhibitor;intercellular communication;Knowledge;leukemia;leukemia treatment;Ligands;Long-Term Survivors;Malignant Childhood Neoplasm;Maps;Mediating;migration;Molecular;Network-based;new therapeutic target;Normal Cell;NOTCH3 gene;novel drug combination;novel therapeutic intervention;patient derived xenograft model;Patients;Pharmaceutical Preparations;Pharmacogenomics;Pharmacology;Population;population based;Positioning Attribute;Program Development;programs;Proliferating;receptor;Recurrence;Recurrent disease;Refractory;Refractory Disease;Relapse;Resistance;response;Reverse engineering;Role;Saint Jude Children's Research Hospital;Sampling;Signal Transduction;single cell analysis;single-cell RNA sequencing;success;Survival Rate;System;Systems Biology;T cell differentiation;T-Cell Development;T-Lymphocyte;targeted agent;targeted treatment;Testing;transcriptomics;Treatment outcome;treatment response;tumor;tumor microenvironment;Validation;Work

PROJECT_TITLE: Clonal Therapy for Pediatric T-cell Acute Lymphoblastic Leukemia


ORG_CITY: NEW YORK

PHR: Project Narrative Analyses using four decades of U.S. SEER data support that three cancers have been increasing dramatically in younger adults over the past decade: 318,781 adults aged 25–49 years were diagnosed with colorectal (n=114,220), thyroid (n=146,977), and kidney (n=57,584) cancer with annual percent increases at 2.44%, 4.81%, and 3.83% per year, respectively, during 2006–2015. To support more effective early prevention, we propose to develop a comprehensive mathematical framework to identify causes behind the rising incidence in these three key early-onset cancers.

PI_NAMEs: YANG, WAN  (contact)

PROGRAM_OFFICER_NAME: HODGES, NICHOLAS AARON

PROJECT_TERMS: Address;Adult;Advanced Malignant Neoplasm;Age;aged;anti-cancer research;Antibiotics;Biological Process;Birth;Cancer Biology;Cancer Detection;cancer initiation;cancer risk;carcinogenesis;Carcinogenesis Mechanism;Classification;clinical investigation;Clonal Expansion;Cohort Effect;Colorectal;Colorectal Cancer;community-level factor;Coupled;Data;data modeling;Data Set;Detection;Diagnosis;Diet;Disease;early onset;Environmental Risk Factor;Epidemic;Epidemiology;Etiology;Evaluation;Exclusion;experience;Exposure to;flexibility;Household;Incidence;Individual;innovation;Kidney;Life;Life Cycle Stages;Life Style;Localized Malignant Neoplasm;Malignant Neoplasms;mathematical model;Mathematics;Methodology;Methods;Modeling;Mutation;National Health and Nutrition Examination Survey;National Health Interview Survey;novel;Obesity;Outcome;Patients;personalized approach;Population;Predisposition;prevent;Prevention;Primary Prevention;Process;Public Health;racial population;response;Risk;Risk Assessment;Risk Estimate;Risk Factors;Sampling;Screening for cancer;SEER Program;Smoke;Sum;Surveys;System;Testing;Thyroid Gland;Time;trend;Validation;Work;young adult

PROJECT_TITLE: UNCOVER: underlying novel causes of onset of very early cancer research


ADMINISTERING_IC: AR

IC_NAME: NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

NIH_SPENDING_CATS: Biodefense and Related Countermeasures;Physical Injury - Accidents and Adverse Effects;Wound Healing and Care

ORG_CITY: BIRMINGHAM

ORG_DEPT: DERMATOLOGY

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

ORG_STATE: AL

PHR: Narrative Building on our previous validation studies conducted in highly relevant animal models, the successful completion of the proposed studies will provide at least one novel, highly effective and safe mechanism-based formulation of small molecules for attenuating painful cutaneous blistering/inflammation caused by exposure to chemical warfare arsenical vesicants and, perhaps, other similar agents. These studies are crucial for moving the newly developed formulation to clinic. The outcome of the proposed research is likely to have a significant impact on human health protection in the event of accidental or intentional mass population exposure to vesicant chemicals used in warfare.

PI_NAMEs: ATHAR, MOHAMMAD  (contact)

PROGRAM_OFFICER_NAME: KOCH, PETER

PROJECT_TERMS: absorption;Accidents;Acids;Acute;Animal Model;Anti-Inflammatory Agents;Antidotes;Antioxidants;Arsenic;Arsenicals;Asia;Attenuated;Award;Biological;Biological Assay;British;Bulla;Cell Death;Characteristics;chelation;chemical threat;Chemical Warfare;Chemical Weapons;Chemicals;China;ChIP-seq;Clinic;Clinical;clinical candidate;clinical translation;Complex;Cutaneous;Cysteine;Dangerousness;Data;Dermatology;design;Development;Dose;Drug Formulations;effective therapy;efficacy evaluation;EIF-2alpha;Emulsions;endoplasmic reticulum stress;Event;experience;Exposure to;Family suidae;FDA approved;Formulation;Funding;Generations;Germany;Health protection;Human;Human Rights;Inflammation;Inflammatory Response;inhibitor;Injury;Intervention;Investigation;Italy;Japan;Laboratories;lead optimization;Lesion;lewisite;Maximum Tolerated Dose;Mediating;Miniature Swine;Modeling;Molecular;Molecular Chaperones;Molecular Target;mouse model;Mus;Mustard Gas;Needles;novel;Outcome;Oxides;Pain;Pathogenesis;Pathway interactions;Pharmaceutical Preparations;Phosphorylation;Poison;Population;porcine model;pre-clinical;programs;propellant;Protective Agents;protein folding;protein misfolding;Proteins;Publishing;Reactive Oxygen Species;Records;Reporting;Research;response;Risk;Role;Safety;Scientist;Security;Seminal;Signal Transduction;skin damage;Skin injury;skin lesion;small molecule;Syria;System;Therapeutic;Therapeutic Agents;therapeutic lead compound;Tissues;Topical application;Toxic effect;Toxicology;transcription factor;transcriptome sequencing;Translations;treatment strategy;United States National Institutes of Health;USSR;Validation;validation studies;Vesicants;weapons;web site;World War I;World War II

PROJECT_TITLE: Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury


ORG_CITY: PITTSBURGH

ORG_DEPT: OTOLARYNGOLOGY

ORG_NAME: UNIVERSITY OF PITTSBURGH AT PITTSBURGH

ORG_STATE: PA

PHR: PROJECT NARRATIVE – OVERALL  The research Projects and supporting state-of-the-art supporting Cores of the UPMC Hillman Cancer Center Head and Neck SPORE are directed at solving key remaining problems in head and neck squamous cell carcinoma treatment – debilitating toxicities, low immunotherapy response rates, and the need for precision oncology. The SPORE’s Developmental Research and Career Enhancement Programs will ensure continuous invigoration and increased diversity of the SPORE and the field of translational head and neck cancer research.

PI_NAMEs: FERRIS, ROBERT L. (contact);SKINNER, HEATH DEVIN

PROGRAM_OFFICER_NAME: HUBBARD, LEAH

PROJECT_TERMS: Address;Adjuvant Radiotherapy;American College of Radiology Imaging Network;American Society of Clinical Oncology;anti-cancer research;Anti-diabetic Drugs;anti-PD-1;anti-PD1 therapy;Automobile Driving;Award;biobank;Bioinformatics;Biological Markers;Biometry;Biopsy;Cancer Center;Cancer Center Support Grant;career;chemoradiation;chemotherapy;Cisplatin;Clinical;Clinical Data;Clinical Trials;Clinical Trials Design;cohort;Collaborations;Combination immunotherapy;Combined Modality Therapy;Cytometry;Data;Databases;design;Development;Diagnosis;Dose;Eastern Cooperative Oncology Group;Ensure;Exercise;flexibility;follow-up;Funding;Future;Generations;Genes;Genomics;Gifts;Head and Neck Cancer;Head and Neck Squamous Cell Carcinoma;Head and neck structure;high dimensionality;high risk;Historically Black Colleges and Universities;HPV oropharyngeal cancer;Hypoxia;IL6 gene;Image;Immune;Immunologist;Immunooncology;Immunotherapy;improved;Industrialization;inhibitor;innovation;Institution;Investments;Low risk HPV;Measures;medical schools;Metabolic;Metformin;minimally invasive;Minority Groups;multidisciplinary;National Clinical Trials Network;Neoadjuvant Therapy;next generation;Nivolumab;novel;Operative Surgical Procedures;Oral;Organ;Outcome;outreach;Pathologic;Patients;PD-1 blockade;Positioning Attribute;precision oncology;predicting response;predictive signature;prevent;Primary Neoplasm;Program Research Project Grants;programmed cell death protein 1;programs;prospective;Quality of life;Radiation therapy;Radiogenomics;radiomics;recruit;Recurrence;Reporting;Reproduction spores;Research;Research Infrastructure;Research Personnel;Research Project Grants;Research Support;Resistance;Resources;response;Risk;Robotics;rosiglitazone;single cell sequencing;Site;standard of care;Subgroup;success;T-Lymphocyte;Technology;technology platform;Testing;Thyroid Nodule;Time;Tissues;Toxic effect;transcriptome sequencing;transcriptomics;Translational Research;trial comparing;tumor;Underrepresented Minority;Universities;Woman;X-Ray Computed Tomography

PROJECT_TITLE: Head and Neck Cancer SPORE


FUNDING_MECHANISM: SBIR-STTR RPGS

NIH_SPENDING_CATS: Contraception/Reproduction;Endometriosis;Pain Research;Women's Health Research

ORG_CITY: Irvine

ORG_NAME: ENDOMET BIOSCIENCES, INC

ORG_STATE: CA

PHR: PROJECT NARRATIVE: The goal of this project is to develop a therapeutic for treating endometriosis. Endometriosis is a high priority research area of NICHD. NIH has also stated as a goal in the 2021-2025 Strategic Plan that “at least one, novel, non-hormonal pharmacologic treatment for endometriosis [will be] identified and moved to clinical trials.” This is an aspirational goal because current management protocols for endometriosis—including hormones and surgery—do not address the root cause of the disease, fail to reverse disease progression, leave a chance of recurrence, and often present patients with undesirable side effects. We have identified a lead candidate that specifically targets a downstream pathway component known to contribute to endometriosis pathogenesis and endometrial migration and invasion. In this Phase IIB application, we will further develop this lead candidate for IND submission to the FDA for allowance to begin clinical trials.

PI_NAMEs: PETROSSIAN, TANYA CHRISTINEH (contact)

PROGRAM_OFFICER_NAME: TINGEN, CANDACE M

PROJECT_TERMS: absorption;Address;Adolescent;Affect;Animals;Apoptosis;appropriate dose;Area;beta catenin;Binding;Binding Proteins;Biological Assay;Biological Sciences;Body Weight;Canis familiaris;Cardiac;Cell Membrane Permeability;Cell Nucleus;Cells;Chronic;Cicatrix;Clinical;Clinical Chemistry;Clinical Trials;Corn Oil;Cyclic Peptides;Cytoplasm;Data;Development;Diagnosis;disability;Disease;Disease Progression;Dose;Drug Kinetics;electrical property;Electrodes;Endometrial;endometriosis;Epidemic;Estrus;Ethnic Origin;Excision;Exhibits;Female;Filler;first-in-human;Formulation;Future;Generations;Genes;Genetic Transcription;Goals;Gonadotropin Releasing Hormone Inhibitor;Grant;Growth;Half-Life;healthy volunteer;Heart;Hematology;Hormonal;Hormones;Human;Hysterectomy;In Vitro;in vivo;Induction of Apoptosis;Infertility;inhibitor;Invaded;Ion Channel;irritation;Lead;lead candidate;Length;Lesion;Libraries;logarithm;Medical;Membrane;Menopause;Menstruation;Methods;migration;Modeling;Monkeys;mouse model;Mus;National Institute of Child Health and Human Development;neurobehavioral;Normal tissue morphology;novel;novel therapeutics;Operative Surgical Procedures;Oral;Ovary;Pain;Pain management;patch clamp;Pathogenesis;Pathway interactions;patient population;Patients;peptide drug;Peptide Hydrolases;Periodicity;Persons;Pharmaceutical Preparations;Pharmacological Treatment;Pharmacology Study;Phase;Phase I Clinical Trials;pill;Plasma;Pluripotent Stem Cells;pre-clinical;preclinical study;Preparation;Production;Proliferating;Proteins;Protocols documentation;Rattus;Recommendation;Recurrence;Regulation;Reporting;reproductive;Research;Research Priority;Risk;Safety;Serum;side effect;Small Business Innovation Research Grant;Specific qualifier value;Strategic Planning;success;System;Testing;Therapeutic;Toxic effect;Toxicokinetics;Toxicology;transcription factor;treatment duration;Treatment Efficacy;United States National Institutes of Health;Uterus;Vagina;Vaginal delivery procedure;Ventricular Arrhythmia;Woman;Women's Health

PROJECT_TITLE: Novel, Non-hormonal Therapeutic for Endometriosis


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Dental, Oral, and Craniofacial Disease;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Rare Diseases

PHR: PROJECT NARRATIVE – ADMINISTRATIVE CORE (CORE A)  The Administrative Core (Core A) is critical in coordinating the efforts of the HCC HN SPORE by providing oversight on all aspects HN SPORE activities as well as housing and improving the HN SPORE organ specific database (OSD), which includes data collected from over 12,000 patients with head and neck cancer.

PI_NAMEs: FERRIS, ROBERT L. (contact)

PROJECT_TERMS: Advocacy;Cancer Center;career;Clinical;clinical database;Clinical Research;Clinical Trials;Collaborations;college;Communication;Data;data exchange;Data Security;Databases;Development;Discipline;Disease;Ensure;Environment;Evaluation;Expedite Dissemination;Expenditure;Fostering;Funding;Goals;Guidelines;Head and Neck Cancer;Head and Neck Squamous Cell Carcinoma;Housing;Human Resources;Image;improved;Individual;individual patient;industry partner;Institution;interdisciplinary approach;interest;International;Leadership;Letters;Medical Oncologist;meetings;Monitor;multidisciplinary;operation;Organ;organizational structure;outreach;outreach program;Participant;Patients;Periodicals;Physicians;Productivity;programs;prospective;Publications;Radiation Oncologist;Records;recruit;Reproduction spores;Research;Research Personnel;Research Project Grants;Resource Allocation;Resources;Scientist;Surgeon;translational progress;Translational Research;Translations;Underrepresented Minority;Universities;website development;Work

PROJECT_TITLE: Core A: Administrative Core


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Dental, Oral, and Craniofacial Disease;Immunotherapy;Orphan Drug;Rare Diseases

PHR: PROJECT NARRATIVE − PROJECT 1  Despite the promise of immune checkpoint inhibition in head and neck squamous cell carcinoma (HNSCC), only a minority of patients ultimately benefit. Continuing Project 1 has already identified tumor metabolism and hypoxia as potential drivers of anti-PD-1 resistance in this disease and now seek to examine the interaction between tumor hypoxia and metabolism, combinatorial immunotherapy, and response. The goal of this project will be to identify the next generation of metabolically driven immunotherapy combination for clinical trial.

PI_NAMEs: DELGOFFE, GREG M. (contact)

PROJECT_TERMS: Affect;Aftercare;American Society of Clinical Oncology;Animal Model;anti-CTLA4;anti-PD-1;anti-PD1 therapy;Automobile Driving;Award;Cell Physiology;cell type;Cells;checkpoint inhibition;clinical practice;Clinical Research;Clinical Trials;Clinical Trials Design;Combination immunotherapy;combinatorial;Data;design;Development;Disease;Environment;Equilibrium;Exhibits;Functional disorder;Future;Goals;Head and Neck Cancer;Head and Neck Squamous Cell Carcinoma;Hypoxia;Image;Immune;immune cell infiltrate;immune checkpoint blockade;Immune checkpoint inhibitor;Immune response;Immunity;Immunologics;Immunotherapy;immunotherapy trials;improved;inhibitor;insight;ipilimumab;Malignant Neoplasms;Metabolic;Metabolism;Metastatic/Recurrent;Metformin;Minority;Modeling;next generation;Nivolumab;novel;novel therapeutics;Outcome;Oxidative Phosphorylation;patient population;Patients;pembrolizumab;personalized immunotherapy;Pharmaceutical Preparations;Phenotype;Phosphorylation Inhibition;pre-clinical;Pre-Clinical Model;predicting response;Productivity;programmed cell death protein 1;programs;radiomics;receptor;recruit;Repression;Reproduction spores;Research;Research Personnel;Resistance;resistance mechanism;response;rosiglitazone;Sampling;Scanning;standard of care;T-Lymphocyte;targeted treatment;Testing;Therapeutic Clinical Trial;Tissues;transcriptome sequencing;tumor;tumor hypoxia;Tumor Immunity;tumor metabolism;tumor microenvironment;X-Ray Computed Tomography

PROJECT_TITLE: Project 1: Hypoxia and metabolic dysregulation as a targetable barrier to immunotherapy in head and neck squamous cell carcinoma (HNSCC)


FUNDING_MECHANISM: TRAINING, INDIVIDUAL

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Eating Disorders;Mental Health;Neurosciences;Nutrition;Obesity

ORG_CITY: PHILADELPHIA

ORG_DEPT: BIOLOGY

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

PHR: PROJECT NARRATIVE Eating habits that are uncontrollable and persist without respect to negative consequences are compulsive and can be observed in both obesity and eating disorders. Motivated behavior is controlled by brain circuits that are sensitive to how hungry we are, but how hunger changes the responsivity of these circuits to negative consequences associated with eating is unknown. This project will test the hypothesis that hunger modulates the communication of negative consequences to motivational brain regions, and will improve our understanding of how these mechanisms can contribute to compulsive eating.

PI_NAMEs: SMITH, NICHOLAS K (contact)

PROGRAM_OFFICER_NAME: CASTLE, ARTHUR

PROJECT_TERMS: Address;Affective;Animal Behavior;Animals;Aversive Stimulus;Behavior;Behavioral;behavioral response;Binge Eating;Brain;Brain region;Brain Stem;Calcium;career;Communication;Complement;Compulsive Behavior;Computer Systems;Data;Development;Diet Habits;Disease;Dopamine;dopamine system;Eating;Eating Disorders;Elements;Equilibrium;Event;experimental study;feeding;Feeding behaviors;Food;Goals;Hunger;Hypothalamic structure;Image;improved;in vivo;Individual;Laboratory Study;Lead;Learning;maladaptive behavior;Mentors;mesolimbic system;motivated behavior;Motivation;Mus;neural;neural circuit;neurobehavioral;Neurobiology;neuroimaging;Neurons;neuroregulation;novel;Obesity;Pain;parabrachial nucleus;Peptides;Process;Punishment;Research;Resistance;response;Rewards;Rodent;Role;Scientist;Signal Transduction;skills;Starvation;Stimulus;success;Technical Expertise;Techniques;Testing;Training;Ventral Tegmental Area

PROJECT_TITLE: Identifying the contribution of a brainstem circuit to compulsive food seeking


NIH_SPENDING_CATS: American Indian or Alaska Native;Behavioral and Social Science;Cancer;Clinical Research;Digestive Diseases;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Infectious Diseases;Nutrition;Prevention;Racial and Ethnic Minority Health Research;Rare Diseases;Rural Health;Stomach Cancer

ORG_CITY: SEATTLE

ORG_NAME: FRED HUTCHINSON CANCER CENTER

ORG_STATE: WA

PHR: PROJECT NARRATIVE Gastric cancer disparities remain a public health concern in American Indian populations, especially in the Navajo Nation, one of the largest tribes in the United States. Despite awareness of these disparities, little is known about risk factors for gastric cancer in the American Indian population, particularly Helicobacter pylori (H. pylori) infection. This project seeks to assess the burden of H. pylori infection in the Navajo Nation and identify strategies to reduce that burden.

PI_NAMEs: PETE, DORNELL  (contact)

PROJECT_TERMS: Accounting;Adherence;Adult;Affect;Alaska;Alaska Native;Alaska Native population;Alleles;American Indian community;American Indian Population;American Indian Tribe;American Indians;Antibiotic Resistance;Antigens;Arizona;Awareness;barrier to care;Behavioral;burden of illness;Canada;cancer health disparity;Cancer Intervention;Cells;Cessation of life;Chronic;chronic infection;Clinic;Clinical Data;Cross-Sectional Studies;Cytotoxin;design;Development;Diet;Diet Surveys;dietary;Dietary Practices;Disease;Disparity;East Asian;Environmental Risk Factor;experience;Exposure to;Food;Frequencies;fruits and vegetables;Future;gastric cancer prevention;General Population;Genes;Genotype;Goals;Grain;Gram-Negative Bacteria;Health;health assessment;Health Surveys;Healthcare Systems;Helicobacter Infections;Helicobacter pylori;High Prevalence;high salt diet;improved;Incidence;Individual;Infection;infection risk;Inflammation;Institution;International;Intervention;Interview;Inuits;Laboratories;Learning;Link;Malignant Neoplasms;malignant stomach neoplasm;Measures;member;Mission;Mucous Membrane;Native-Born;Navajo;Nested Case-Control Study;New Mexico;Outcome;Pathogenicity;Pathogenicity Island;Patient Compliance;Patients;Pattern;Persons;Phase;Population;Population Group;Postdoctoral Fellow;pre-doctoral;Prevalence;Prevention;Processed Meats;Production;Proteins;Public Health;Qualitative Research;Questionnaires;Reporting;Research;Risk;Risk Factors;Role;Sodium Chloride;Stomach;stool sample;success;surveillance data;Testing;treatment adherence;Treatment Failure;Tribes;United States;United States National Institutes of Health;Vegetables;Virulence;Virulence Factors;virulence gene;Work

PROJECT_TITLE: Assessing Helicobacter pylori and Diet to Develop Cancer Interventions in American Indian Communities in the Southwest


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Cancer Genomics;Clinical Research;Clinical Trials and Supportive Activities;Dental, Oral, and Craniofacial Disease;Digestive Diseases;Genetics;Human Genome;Immunotherapy;Infectious Diseases;Orphan Drug;Patient Safety;Precision Medicine;Radiation Oncology;Rare Diseases;Sexually Transmitted Infections

PHR: PROJECT NARRATIVE − PROJECT 2  Treatment of human papillomavirus (HPV) positive squamous cell carcinoma of the oropharynx (OPC) is highly toxic; however, the use of Trans-Oral Robotic Surgery (TORS) could provide improvements in toxicity if patients with high risk neck disease (HRND) could be identified prior to surgery, and treated with other modalities. This project: 1) subjects clinical samples from over 400 patients with HPV positive OPC treated with TORS in two separate cohorts, including ECOG 3311, to comprehensive genomic, transcriptomic and radiomic analysis to examine a preliminary signature for predicting HRND, coupled with 2) in vivo analysis of mutations already identified as associated with HRND and immune infiltrate and 3) quality of life, toxicity and biospecimen analysis of a prospective trial combining TORS, RT and immunotherapy in this disease. The overarching goal of this Project is to truly apply precision oncology to HPV+ OPC.

PI_NAMEs: SKINNER, HEATH DEVIN (contact)

PROJECT_TERMS: Address;Adjuvant;Adjuvant Therapy;American Society of Clinical Oncology;anti-PD-1;anti-PD1 therapy;arm;Biological;Cancer Center;Cancer Model;Cancer Patient;cancer therapy;chemoradiation;Chemotherapy and/or radiation;Cisplatin;clinic ready;Clinical;Clinical Trials;clinically significant;cohort;Combination Drug Therapy;Coupled;Data;Databases;design;Disease;Eastern Cooperative Oncology Group;Enrollment;Excision;exome sequencing;Extranodal;Feedback;Flow Cytometry;Gene Expression;Gene Mutation;Genes;genetic signature;Genomics;global health;Goals;Head and Neck Cancer;Head and neck structure;High Dose Chemotherapy;high risk;HPV oropharyngeal cancer;human papilloma virus oropharyngeal squamous cell carcinoma;Human Papilloma Virus-Related Malignant Neoplasm;Image;Immune;immune cell infiltrate;Immunotherapy;improved;in vivo evaluation;interest;Interferons;Knock-out;Letters;Low Dose Radiation;lymph nodes;Malignant Neoplasms;malignant oropharynx neoplasm;Mediating;Methods;Modality;Mutation;Mutation Analysis;Neck;Neck Disorder;Nivolumab;Nodal;novel;Operative Surgical Procedures;Oral;Organ;Outcome;participant enrollment;Pathology;Pathway interactions;Patient Selection;Patients;PD-1 blockade;peripheral blood;Positive Lymph Node;Postoperative Period;Pre-Clinical Model;precision oncology;predictive signature;Primary Neoplasm;Prognosis;prospective;Protocols documentation;Quality of life;Radiation Dose Unit;Radiation therapy;radiomics;Randomized;randomized, clinical trials;Reporting;Repression;Resected;Risk;Robotics;Sampling;Scanning;Signal Transduction;Site;success;survival outcome;synergism;Techniques;The Cancer Genome Atlas;Therapeutic;Tissues;TNF receptor-associated factor 3;Toxic effect;transcriptome sequencing;transcriptomics;Treatment-related toxicity;tumor;tumor growth;United States;Work;X-Ray Computed Tomography

PROJECT_TITLE: Project 2: Optimizing patient selection and deintensified therapy for human papillomavirus positive (HPV+) oropharyngeal cancer (OPC)